ArticleObesity surgery2026
Optimal Timing for Initiating Liraglutide 3.0 mg in Patients With Persistent Obesity Six Months After Metabolic and Bariatric Surgery.
Article in Obesity surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
objectivesTo determine the optimal timing for initiating liraglutide in patients with persistent obesity (BMI ≥ 28 kg/m² in China) six months after metabolic and bariatric surgery, a key gap in postoperative weight management.
methodsIn this prospective study, 100 patients were allocated to receive liraglutide (3.0 mg/day) starting at 6 (LG-6), 9 (LG-9), or 12 (LG-12) months post-surgery, or standard care without liraglutide (n = 25 each). The primary endpoint was percent total weight loss (%TWL) at 18 months. Secondary outcomes included changes in body composition and remission of obesity-related comorbidities.
resultsAll three liraglutide groups showed greater %TWL (LG-6 16.3 ± 5.7%, LG-9 13.7 ± 5.3%, LG-12 12.6 ± 6.0%) compared with controls (5.3 ± 5.2%; P < 0.05). Higher proportions of patients in liraglutide groups achieved BMI < 28 kg/m² (LG-6 40%, LG-9 52%, LG-12 36%) and ≥ 15% TWL (64%, 32%, 28%) versus controls (16%, 4%; P < 0.05). The LG-6 group showed the highest proportion reaching ≥ 20% TWL (24% vs. 0% in controls; P < 0.05). Reductions in fat mass and alanine transaminase, preservation of muscle mass, and remission of metabolic dysfunction-associated steatotic liver disease and hyperuricaemia were observed in association with liraglutide treatment.
conclusionsEarly liraglutide initiation, particularly at six months post-surgery, was linked to greater weight loss and more favourable metabolic profiles compared with standard care. These findings suggest that timely pharmacotherapy may be associated with improved long-term weight management outcomes, though causality remains to be established.
Indexed as
Identifiers
42446801What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.